Aromatase Inhibitors in Breast Cancer

Key Points

• To evaluate the emerging therapeutic role and pharmacological efficacy of third-generation aromatase inhibitors compared to standard tamoxifen therapy in postmenopausal women with breast cancer.
• Narrative synthesis of clinical and pharmacological evidence on endocrine treatments for breast cancer.
• Evaluation of modern aromatase inhibitors, including letrozole, anastrozole, and exemestane, relative to earlier agents like aminoglutethimide and tamoxifen.
• Newer aromatase inhibitors exhibit significantly higher potency and target specificity compared to first-generation agents such as aminoglutethimide.
• Agents including letrozole, anastrozole, and exemestane are actively redefining standard endocrine management paradigms for postmenopausal breast cancer.